ClinicalTrials.gg
CompletedNCT06126497Updated Sep 1, 2026Results posted

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

A Phase 2 interventional study of Ropanicant in Major Depressive Disorder, sponsored by Suven Life Sciences Limited. Completed at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Suven Life Sciences Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
838th of 1,323
41 · median 70
Started
2024
with 69 others
Phase 2
271 of 1,500
45 open now
Registered
1,288th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 838th largest by enrollment of the 1,323 interventional ones that give a count, is one of 70 that started in 2024, is one of 271 in phase 2, and was the 1,288th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).

Read the detailed description

Approximately 36 participants will be randomly assigned to receive Ropanicant either Ropanicant 45 mg once a day (QD), Ropanicant 30 mg twice a day (BID), or Ropanicant 45 mg BID for 2 weeks, in a ratio of 1:1:1 (12 participants in each treatment group). Following a screening period of up to 4 weeks, the participants will be treated for 2 weeks.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • SUVN-911
  • Phase-2
  • MDD
  • Depression
  • Open label
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet the criteria for MDD without psychotic features and diagnosis confirmed by the Mini-International Neuropsychiatric Interview (MINI).
  • Participants with a current major depressive episode of at least 4 weeks of duration prior to the screening visit.
  • Participants must have an MADRS score of ≥25 at the screening and the baseline visits.
  • Participants must have a score of ≥4 on Clinical Global Impression - Severity (CGI-S) Scale at the screening and the baseline visits.

Exclusion criteria

Exclusion Criteria:

  • Participants who meet criteria for treatment-resistant depression during the current major depressive episode, which will be defined as being non-responders (less than 50% of symptom improvement) to 2 or more depression treatment periods of adequate dose and duration as defined by the Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ).
  • Participants taking antidepressant treatment (SSRIs and SNRIs) or any medication that is with the use of monoamine oxidase inhibitors (eg, opioids, stimulants) within 2 weeks (or 5 half-lives, whichever is longer) prior to baseline and until the end of study visit.
  • Participants who do not agree to avoid tyramine rich diet from the start of dosing and until 2 weeks following last study drug administration.
  • Participants who are habitual smokers or using nicotine products.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Ropanicant 45 mg QD

    The participant will take 1 tablet/day in the morning (for qd dosing)

    Drug: Ropanicant

  • Experimental
    Ropanicant 30 mg BID

    The participant will take 2 tablets/day (\~12 hours apart for bid dosing).

    Drug: Ropanicant

  • Experimental
    Ropanicant 45 mg BID

    The participant will take 2 tablets/day (\~12 hours apart for bid dosing).

    Drug: Ropanicant

Interventions

  • DrugRopanicant

    Tablet

    Also known as: SUVN-911

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Participants with at least one Treatment-emergent adverse events (TEAEs) reported during the duration of the study.

    Time frame: From Screening to Day 21

Secondary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS) Score

    Change from the baseline to the MADRS total score. The MADRS is a clinician-rated scale to assess depressive symptoms which consists of 10 items. The time frame for this scale is the past 7 days. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). The total score is the sum of 10 items and can take range from 0 to 60. A higher score represents a higher severity of the level of depression.

    Time frame: From Baseline to Day 14

07

Results

Posted Sep 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneRopanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BID
Started141413
Completed121213
Not completed220

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events

Participants with at least one Treatment-emergent adverse events (TEAEs) reported during the duration of the study.

Time frame:
From Screening to Day 21
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsRopanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BID
Number of Participants With Treatment-Emergent Adverse Events666
SecondaryMontgomery-Åsberg Depression Rating Scale (MADRS) Score

Change from the baseline to the MADRS total score. The MADRS is a clinician-rated scale to assess depressive symptoms which consists of 10 items. The time frame for this scale is the past 7 days. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). The total score is the sum of 10 items and can take range from 0 to 60. A higher score represents a higher severity of the level of depression.

Time frame:
From Baseline to Day 14
Reported as:
Mean · score on a scale
Montgomery-Åsberg Depression Rating Scale (MADRS) Score
score on a scaleRopanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BID
Montgomery-Åsberg Depression Rating Scale (MADRS) Score-10.5 ± 7.47-12.7 ± 9.54-10.4 ± 6.51

Adverse events

Collected over From Screening to Day 21. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ropanicant 45 mg, QD0/14 (0%)0/14 (0%)6/14 (42.9%)
Ropanicant 30 mg, BID0/13 (0%)0/13 (0%)6/13 (46.2%)
Ropanicant 45 mg, BID0/13 (0%)0/13 (0%)6/13 (46.2%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventRopanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BID
Sucidal ideationPsychiatric disorders1/142/131/13
DiarrhoeaGastrointestinal disorders0/140/132/13
SomnolenceGastrointestinal disorders0/142/130/13
InsomniaPsychiatric disorders1/140/131/13
NauseaGastrointestinal disorders1/141/131/13
HeadacheNervous system disorders1/141/130/13
Blood creatine phosphokinase increasedInvestigations1/140/131/13
FatigueGeneral disorders0/141/131/13
PollakiuriaRenal and urinary disorders1/141/130/13
Hallucination, visualPsychiatric disorders0/140/131/13

Baseline characteristics

The Baseline analysis population considered is Safety Set which included all participants who received any study drug.

Age, Categorical
Age, Categorical(Participants)Ropanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BIDTotal
<=18 years0000
Between 18 and 65 years14131340
>=65 years0000
Age, Continuous
Age, Continuous(years)Ropanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BIDTotal
Mean42.8 ± 13.7439.5 ± 13.2852.5 ± 11.2844.9 ± 13.67
Sex: Female, Male
Sex: Female, Male(Participants)Ropanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BIDTotal
Female109928
Male44412
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ropanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BIDTotal
Hispanic or Latino2024
Not Hispanic or Latino12131136
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ropanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BIDTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American76821
White76518
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Ropanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BIDTotal
United States14131340
Montgomery-Asberg Depression Rating Scale (MADRS)
Montgomery-Asberg Depression Rating Scale (MADRS)(units on a scale)Ropanicant 45 mg, QDRopanicant 30 mg, BIDRopanicant 45 mg, BIDTotal
Mean31.7 ± 3.5033.6 ± 6.2731.0 ± 3.4232.1 ± 4.58
08

Study locations

10 sites
  • Clinical Innovations, Inc
    Bellflower, California 90706, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Collaborative Neuroscience Research, LLC
    Torrance, California 90504, United States
  • Innovative Clinical Research, Inc.
    Miami Lakes, Florida 33016, United States
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Neuro behavioral Clinical Research, Inc
    North Canton, Ohio 44720, United States
  • Cedar Clinical Research, Inc.
    Murray, Utah 84107, United States
  • Eastside Therapeutic Resource, Inc. dba Core Clinical Research
    Everett, Washington 98201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jul 2024, 5 months.

Results were first posted in Sep 2026, 2 years 1 month after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 5 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Nov 13, 2023
StartActual
Feb 5, 2024
Primary completionActual
Jul 19, 2024
CompletionActual
Jul 19, 2024
Results first posted
Sep 1, 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06126497
Lead sponsor
Suven Life Sciences Limited
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Feb 5, 2024
Primary completion
Jul 19, 2024
Completion
Jul 19, 2024
Results posted
Sep 1, 2026
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion